All In Biotech

Drug Trial Radar · NCT03303079

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

571

Actual

Start

Dec 19, 2017

Primary completion

Nov 30, 2019

Study completion Nov 30, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 \[monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months\] compared with placebo for preventive treatment in Chronic Migraine patients

Conditions

  • Migraine

Interventions

  • TEV-48125Drug

    TEV-48125 will be subcutaneously administered once monthly for 3 months.

  • TEV-48125 or placeboDrug

    TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.

  • PlaceboDrug

    Placebo will be subcutaneously administered once monthly for 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of Investigational Medicinal Product (IMP)Time frame: Baseline, 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saitama Medical University Hospital

    Iruma, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.